![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The collaboration aims to develop long-acting injectable drugs to improve treatment outcomes for individuals with substance abuse disorders using it’s novel, long-acting injectable technology.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: N/A Product Type: Undisclosed
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 17, 2024
Details:
SX600 (dexamethasone) is a novel formulation of extended-release microspheres designed for transforaminal epidural injection in the management of sciatica pain.
Lead Product(s): Dexamethasone
Therapeutic Area: Musculoskeletal Product Name: SX600
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
SX600, is novel formulation of dexamethasone acetate microspheres for micro-suspension injection, was designed as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved profile relative to radicular leg pain.
Lead Product(s): Dexamethasone
Therapeutic Area: Neurology Product Name: SX600
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process development and scale-up activities. Together, these activities will position SX600 for future Phase 3 clinical trials.
Lead Product(s): Dexamethasone
Therapeutic Area: Musculoskeletal Product Name: SX600
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 26, 2022